In a regulatory filing, Corcept Therapeutics (CORT) disclosed that its director Leonard Baker bought 100K shares of common stock on March 17th in a total transaction size of $3.3M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics Lawsuit: CORT Investors Face Losses After FDA Rejection and Alleged Misleading Statements
- Corcept Therapeutics Balances Growth With Rising Risks
- Corcept Therapeutics price target lowered to $60 from $67 at H.C. Wainwright
- Corcept Therapeutics reports Q4 EPS 20c, consensus 33c
- Corcept Therapeutics Posts Strong 2025 Results, Issues Optimistic Outlook